MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

@article{Li2020MicroRNA1533pET,
  title={MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy},
  author={Yu-ling Li and Jia-ming Tang and Xiaoyun Chen and Bing Luo and Guo-hua Liang and Qian Qu and Zi-yuan Lu},
  journal={Human Cell},
  year={2020},
  volume={33},
  pages={610-618}
}
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease caused by abnormal DNA replication of bone marrow stem cells and chemotherapy resistance is a major obstacle to the effective treatment of patients with CML. Imatinib (IM), a tyrosine kinase inhibitor (TKI), is a first-line drug clinically used for CML. Mounting evidence has indicated that the dysregulation of microRNAs (miRNAs) is associated with the chemoresistance of CML. In this study, miR-153-3p, which had been implicated… Expand
4 Citations

References

SHOWING 1-10 OF 31 REFERENCES
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
miR-153-3p Suppresses Inhibitor of Growth Protein 2 Expression to Function as Tumor Suppressor in Acute Lymphoblastic Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Targeted therapy against Bcl-2-related proteins in breast cancer cells
MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma
Autophagy induction by Bcr‐Abl‐expressing cells facilitates their recovery from a targeted or nontargeted treatment
...
1
2
3
4
...